Announcements Trials
Browse Landscape

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 2

Sponsor

Cancer Type

Genitourinary 4Breast 3Other hematologic neoplasm 2Gynecologic 2Endocrine 2Sarcoma 1NET 1Lymphoid 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Neuroendocrine Tumors 1Carcinoma, Neuroendocrine 1

Interventions

Magnetic Resonance Spectroscopy 15lutetium Lu 177 dotatate 14Specimen Handling 14cabozantinib 10Nivolumab 10pembrolizumab 8Everolimus 8gallium Ga 68 dotatate 7Ipilimumab 6Cisplatin 6Carboplatin 6Etoposide 5trametinib 4olaparib 4lenvatinib 4X-Rays 4Lutetium-177 4Cyclophosphamide 4CTLA-4 Antigen 4fluorodopa F 18 3fludarabine 3dabrafenib 3cemiplimab 3Temozolomide 3Surveys and Questionnaires 3Phantoms, Imaging 3Immunoglobulin G 3Fluorodeoxyglucose F18 3Disulfides 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Positron-Emission Tomography × Endocrine × 90 days × Clear all
NCT04069299 2026-03-31

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

H. Lee Moffitt Cancer Center and Research Institute

Completed
30 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT06448208 2026-03-09

Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors

Memorial Sloan Kettering Cancer Center

Active not recruiting
11 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡